Bayer 2026 FCF reflects about 5h irrigation payouts

Bayer 2026 FCF reflects about 5h irrigation payouts

Bayer’s 2026 Free Cash Flow Reflects Major Litigation Payouts

Bayer AG’s 2026 free cash flow (FCF) is expected to be significantly impacted by litigation-related payments tied to its glyphosate and PCB settlements, with approximately €5 billion in outflows anticipated this year. The company announced a nationwide class-action settlement for U.S. glyphosate litigation in late 2025, structured to distribute capped annual payments over 21 years, with the largest disbursements occurring in 2026. This settlement, combined with additional glyphosate and PCB settlements, has increased Bayer’s litigation provisions to €11.8 billion, up from €7.8 billion previously.

The CFO, Wolfgang Nickl, emphasized that 2026 will see “negative free cash flow” due to these obligations, with litigation-related cash outflows totaling around €5 billion. This aligns with the company’s revised financial guidance, which moved its full-year results announcement to March 4, 2026, to provide clarity on the impact of these settlements. While 2026 marks the peak of cash outflows, Bayer anticipates annual litigation payments declining to roughly €1 billion for the following five years, with further reductions thereafter.

To fund these obligations, Bayer secured an $8 billion bank loan facility and plans to issue senior bonds and equity-credit instruments, avoiding a capital increase that could dilute shareholders. The company also highlighted that the settlements are part of a broader strategy to resolve litigation risks, including a pending U.S. Supreme Court review that could limit future claims.

Despite the near-term financial strain, Bayer remains focused on long-term growth, with CEO Bill Anderson noting that resolving litigation will allow the company to redirect resources to pharmaceutical innovation and agricultural advancements. However, investors should monitor the approval process for the class settlement in Missouri and potential appeals, which could alter the timeline or cost of the resolution.

In summary, Bayer’s 2026 FCF will reflect the largest cash outflows under its litigation containment plan, but the structured, declining payment schedule aims to provide long-term financial clarity. The company’s ability to manage these obligations without relying on equity issuance underscores its commitment to preserving shareholder value amid a complex legal landscape.

(https://www.bayer.com/media/en-us/bayer-investor-and-media-update-english-version/): Bayer Investor and Media Update, 2025.
(https://www.bayer.com/media/en-us/bayer-meets-adjusted-guidance-and-takes-decisive-action-to-tackle-challenges/): Bayer Annual Report 2024.
(https://www.bayer.com/media/en-us/bayer-confirms-2025-group-outlook-progresses-on-strategic-priorities/): Bayer Q3 2025 Financial Update.